Aldesleukin

Generic Name: Aldesleukin

Brand Names: Proleukin

Drug Type: Biotech

CAS Number: 110942-02-4

Unique Ingredient Identifier: M89N0Q7EQR

Background: Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.

Indication: For treatment of adults with metastatic renal cell carcinoma.

Associated Conditions: Metastatic Melanoma, Metastatic Renal Cell Carcinoma ( mRCC)

Clinical Trials

Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)

Phase 2

Conditions: Type1 Diabetes

Interventions: Other: Placebo
Drug: Aldesleukin

First Posted Date: 2018-12-20

Last Posted Date: 2021-12-16

Lead Sponsor: University of Oxford

Target Recruit Count: 41

Registration Number: NCT03782636

Locations: 🇬🇧
Bristol Royal Hospital for Children, Bristol, United Kingdom
🇬🇧
Nottingham Children's Hospital, Nottingham, United Kingdom
🇬🇧
The Great North Children's Hospital, Newcastle Upon Tyne, United Kingdom

and more 2 locations

Safety and Efficacy of Low-dose IL-2 in Birch Pollen Allergy

Phase 2

Completed

Conditions: Allergic Rhinoconjunctivitis to Birch Pollen
With a Positive Skin Prick Test to Birch Pollen

Interventions: Drug: ILT-101 ld-(IL2)

First Posted Date: 2018-12-17

Last Posted Date: 2023-12-04

Lead Sponsor: Assistance Publique - Hôpitaux de Paris

Target Recruit Count: 24

Registration Number: NCT03776643

Locations: 🇫🇷
CIC Biothérapies - Service de Biothérapies, Paris, Groupe Hospitalier Pitié-Salpêtrière 47 -83 BD DE L'hopital, France
🇫🇷
Centre d'essais cliniques, ALYATEC, Strasbourg, Environmental Exposure Chamber, Alyatec, 1 Place De L'hôpital, France

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients

Phase 1

Recruiting

Conditions: Rectal Cancer
Colon Cancer
Gastric Cancer
Gastrointestinal Cancer
Pancreatic Cancer

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Aldesleukin
Biological: anti-KRAS G12D mTCR PBL

First Posted Date: 2018-11-19

Last Posted Date: 2025-05-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 70

Registration Number: NCT03745326

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 1

Active, not recruiting

Conditions: Platinum-Resistant Fallopian Tube Carcinoma
Platinum-Resistant Ovarian Carcinoma
Platinum-Resistant Primary Peritoneal Carcinoma
Recurrent Fallopian Tube Carcinoma
Refractory Ovarian Carcinoma
Platinum-Sensitive Ovarian Carcinoma
Recurrent Ovarian Carcinoma
Recurrent Primary Peritoneal Carcinoma
Refractory Primary Peritoneal Carcinoma
Refractory Fallopian Tube Carcinoma

Interventions: Biological: Aldesleukin
Biological: Autologous NY-ESO-1-specific CD8-positive T Lymphocytes
Other: Cellular Therapy
Drug: Melphalan

First Posted Date: 2018-10-01

Last Posted Date: 2024-03-12

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 4

Registration Number: NCT03691376

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Immunotherapy for the Treatment of Advanced Solid Tumor

Phase 1

Recruiting

Conditions: Recurrence Tumor
Metastatic Cancer
Solid Tumor

Interventions: Biological: TIL
Drug: Aldesleukin
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2018-09-05

Last Posted Date: 2024-08-13

Lead Sponsor: Tongji Hospital

Target Recruit Count: 40

Registration Number: NCT03658785

Locations: 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Phase 2

Active, not recruiting

Conditions: Ovarian Carcinosarcoma
Poorly Differentiated Thyroid Gland Carcinoma
Platinum-Resistant Ovarian Carcinoma
Recurrent Ovarian Carcinoma
Triple Negative Breast Cancer
Bone Sarcoma
Malignancy in Giant Cell Tumor of Bone
Thyroid Gland Anaplastic Carcinoma
Refractory Osteosarcoma
Dedifferentiated Chondrosarcoma

Interventions: Biological: Aldesleukin
Biological: Autologous Tumor Infiltrating Lymphocytes LN-145
Biological: Autologous Tumor Infiltrating Lymphocytes LN-145-S1
Drug: Cyclophosphamide
Other: Quality-of-Life Assessment
Drug: Fludarabine
Biological: Ipilimumab
Biological: Nivolumab
Other: Questionnaire Administration

First Posted Date: 2018-02-28

Last Posted Date: 2025-05-16

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT03449108

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Phase 2

Recruiting

Conditions: Non-Small Cell Lung Cancer
Breast Cancer
Ovarian Cancer
Gastrointestinal/Genitourinary Cancers
Endocrine Tumors
Neuroendocrine Tumors
Multiple Myeloma